Glycosylation and the Demands of Antibody Engineering - Roy Jefferis examines precise questions about how sugars drive antibody function. - BioPharm International

ADVERTISEMENT

Glycosylation and the Demands of Antibody Engineering
Roy Jefferis examines precise questions about how sugars drive antibody function.


BioPharm International
Volume 20, Issue 10

KJM: Do you foresee a lot of advances in fundamental and applied glycosylation science on the horizon?

RJ: These developments can be anticipated to have a significant impact on antibody performance and ultimately on the cost of goods. They will also be applied for the improvement of other biologics. Thus, glycosylation has profound effects on the performance of erythropoietin (EPO). Amgen has recognized this and has re-engineered the molecule to introduce two extra glycosylation sites. The product has improved biologic efficacy and a longer half-life.

The next challenge is the development of biosimilars and competition in the marketplace resulting in a lowering of costs. Competition will come from low-cost economies; even if not licensed within the US, they will compete since they will be available from the web.

K. John Morrow, Jr., PhD, is the president of Newport Biotech, Newport, KY, 513.237.3303;


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines
Source: BioPharm International,
Click here